Clinical Trial Update: A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants [Phase 3]

View source ↗

Summary

Pfizer has withdrawn a Phase 3 trial evaluating Zavegepant for treating multiple migraine attacks in adults. The study was intended to assess efficacy in acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Zavegepant (zavegepant)

Snippet

Sponsor: Pfizer | Conditions: Migraine | Phase 3 | Status: WITHDRAWN